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TREM-1 promotes intestinal 
tumorigenesis
Leslie Saurer1, Daniel Zysset1, Silvia Rihs1, Lukas Mager1,2, Matteo Gusberti1, Cedric 
Simillion3,4, Alessandro Lugli1, Inti Zlobec1, Philippe Krebs1 & Christoph Mueller1
Triggering receptor expressed on myeloid cells-1 (TREM-1) is a potent amplifier of pro-inflammatory 
innate immune responses. Increasing evidence suggests a role for TREM-1 not only in acute pathogen-
induced reactions but also in chronic and non-infectious inflammatory disorders, including various 
types of cancer. Here, we demonstrate that genetic deficiency in Trem1 protects from colorectal cancer. 
In particular, Trem1−/− mice exhibited reduced tumor numbers and load in an experimental model of 
inflammation-driven tumorigenesis. Gene expression analysis of Trem1−/− versus Trem1+/+ tumor tissue 
demonstrated distinct immune signatures. Whereas Trem1−/− tumors showed an increased abundance 
of transcripts linked to adaptive immunity, Trem1+/+ tumors were characterized by overexpression 
of innate pro-inflammatory genes associated with tumorigenesis. Compared to adjacent tumor-
free colonic mucosa, expression of Trem1 was increased in murine and human colorectal tumors. 
Unexpectedly, TREM-1 was not detected on tumor-associated Ly6C− MHC class II+ macrophages. 
In contrast, TREM-1 was highly expressed by tumor-infiltrating neutrophils which represented the 
predominant myeloid population in Trem1+/+ but not in Trem1−/− tumors. Collectively, our findings 
demonstrate a clear role of TREM-1 for intestinal tumorigenesis and indicate TREM-1-expressing 
neutrophils as critical players in colorectal tumor development.
Inflammation is now considered one of the hallmarks of cancer1. While a tumor-elicited inflammatory response 
can be observed for most malignancies, colorectal cancer (CRC) represents a paradigm for cancer that is substan-
tially promoted by chronic inflammation2. For instance, patients with ulcerative colitis have an increased propen-
sity to develop colorectal carcinomas and the long-term use of non-steroidal anti-inflammatory drugs effectively 
reduces colon cancer risk2. In mice, CRC can be modeled by the induction of microbial-driven chronic intestinal 
inflammation3,4. However, also in genetic models of CRC, early tumor-elicited intestinal inflammation represents 
a major driver of tumor growth5.
Despite the relation between intestinal inflammation and CRC, increased expression of CD8 T cell-, T folli-
cular helper (Tfh) cell- and B cell-associated markers in human CRC is linked to a favorable clinical prognosis, 
highlighting the importance of adaptive anti-tumor immunity6. On the other hand, cells and mediators of the 
innate immune system take a critical role in promoting tumor development and progression. Innate cytokines 
such as TNF, IL1β, IL-6, IL-22 can directly act on intestinal epithelial cells to activate NF-κB-dependent onco-
genic pathways, to promote WNT-β-catenin or STAT3-dependent proliferation and to induce mesenchymal 
and stemness features7. Inhibition of these cytokines, their downstream molecules or depletion of their cellular 
sources has been shown to prevent and ameliorate tumor development in various murine models of CRC8–13. 
While pro-inflammatory cytokines thus represent attractive targets for immune-based therapies, a major imped-
iment are their relatively redundant effects in the activation of downstream signaling pathways. Moreover, 
innate cytokines not only exert disease-promoting but also tissue-protective functions. The latter aspect seems 
to be of particular importance in the gastrointestinal tract where pro-inflammatory mediators and pathways 
critically contribute to effective epithelial repair and microbial control. Thus, any treatment strategies aiming at 
cancer-related inflammation in CRC face the challenge of identifying pathways that can be specifically targeted 
without compromising tissue homeostasis or generally jeopardizing anti-microbial and anti-tumor immunity2.
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Our laboratory has a longstanding interest in TREM-1, an activating member of the Ig superfamily that 
is exclusively expressed on neutrophils and subsets of monocytes and macrophages14. Activation of TREM-1 
through its yet incompletely defined ligands, so far comprising HMGB115,16 and multimerized peptidoglycan rec-
ognition protein-1 (PGLYRP)17, potently amplifies oxidative burst and pro-inflammatory cytokine production, 
particularly when signaling in concert with other pattern recognition receptors18. Whereas the role of TREM-1 
has initially been acknowledged from models of septic shock where blockade of TREM-1 conferred signifi-
cant protection19, increasing evidence suggests an involvement of TREM-1 also in chronic and non-infectious 
inflammatory conditions20–23. We have previously demonstrated that TREM-1-expressing cells accumulate in 
the inflamed intestinal mucosa of patients with inflammatory bowel diseases (IBD) and that TREM-1-mediated 
signaling critically contributes to intestinal inflammation24. Accordingly, Trem1-deficient (Trem1−/−) mice exhib-
ited significantly reduced clinical and histopathological signs of experimental colitis25. Strikingly, and in con-
trast to Tnf-deficient mice26, Trem1−/− mice were not impaired in their capacity for microbial control during 
dextran-sodium sulfate (DSS)-induced colitis or during distinct models of infection25. The restricted expression 
of TREM-1 on myeloid cells and its function as an amplifier rather than an initiator of inflammatory reactions 
indicate TREM-1 as an attractive upstream target for dampening disproportionate innate immune responses 
during chronic inflammation and malignant disease. Indeed, in human non-small cell lung cancer (NSCLC) 
increased TREM-1+ tumor-associated macrophages (TAMs) were linked with reduced survival, and inhibiting 
TREM-1 suppressed tumor growth in a mouse xenograft NSCLC model27,28. Likewise, TREM-1 was significantly 
involved in Kupffer cell activation and tumor development in a chemically-induced model of hepatocellular car-
cinoma (HCC)16.
In the present study, we hypothesized that TREM-1 contributes to colitis-associated cancer in the azoxyme-
thane (AOM)/DSS model of CRC. In line with the findings of Zhou et al.29, we demonstrate that absence of 
TREM-1-mediated signaling in AOM/DSS-treated Trem1−/− mice significantly attenuates intestinal tumor devel-
opment. In wildtype Trem1+/+ mice, Trem1 was expressed in tumors but not in the tumor-free adjacent mucosa. 
Moreover, while the immune signature of Trem1−/− tumors was skewed towards increased expression of B cell 
and Tfh-associated genes, Trem1+/+ tumors exhibited an increased abundance of neutrophils and overexpression 
of several innate pro-inflammatory genes that are typically associated with colorectal tumorigenesis. Our study 
further reveals that in contrast to the reported expression of TREM-1 on macrophages in NSCLC and HCC16,27, 
in murine CRC tumor-infiltrating neutrophils but not macrophages express TREM-1. Collectively, our findings 
indicate a disease-promoting role for TREM-1-expressing neutrophils in colitis-associated cancer.
Results
Deficiency in Trem1 attenuates colitis-associated tumorigenesis. To address the role of TREM-1 
in CRC development, we used Trem1-deficient mice (Trem1−/−) mice that were generated in our laboratory25 and 
the AOM/DSS model of murine CRC3. Trem1−/− and Trem1+/+ mice were injected twice with the procarcinogen 
AOM and subjected to three cycles of DSS administration, followed by an additional latency period to allow for 
visible tumor growth (Fig. 1a). As anticipated from our previous studies25, Trem1−/− mice exhibited reduced body 
weight loss after DSS treatment and decreased colon shortening at the final time-point compared to Trem1+/+ 
mice (Supplementary Figure 1a,b). Tumors were observed in both groups of mice (Fig. 1b). However, Trem1−/− 
mice displayed significantly fewer tumors with an average of 4 tumors per colon as opposed to 10 tumors per 
colon in the Trem1+/+ group (Fig. 1c). In line with this observation, the overall tumor load in Trem1−/− mice 
was significantly lower compared to Trem1+/+ mice (Fig. 1d). Analysis of tumor size distribution indicated that 
presence of TREM-1 mostly impacted on the incidence of small tumors (≤5 mm3) rather than affecting the 
growth of large tumors (Fig. 1e). Taken together, TREM-1 significantly contributed to colitis-associated tumor 
development.
Distinct immune transcriptome in Trem1+/+ versus Trem1−/− tumors. In order to investigate the 
underlying mechanisms behind TREM-1-driven tumor development, H&E stained sections of Trem1+/+ and 
Trem1−/− tumors were at first assessed for the tumor grade (Supplementary Figure 1c,d). While AOM-induced 
tumors typically follow the adenoma-carcinoma sequence described for human CRC, in AOM/DSS-treated 
C57BL/6 mice carcinomas are rarely observed3. In Trem1+/+ and also Trem1−/− mice, most tumors represented 
advanced adenomas (Supplementary Figure 1c,d). Immunohistochemistry stainings for Ki-67 or pSTAT3 did 
not indicate apparent differences between the two groups of mice (data not shown). We next subjected tumors of 
comparable size distribution (Supplementary Figure 2a) to a comprehensive NanoString-based gene expression 
profiling. Strikingly, clear differences in the immune transcriptome of Trem1+/+ versus Trem1−/− tumors were 
detected with 50 genes that were distinctly expressed (Fig. 2a and Supplementary Table 1). Trem1+/+ tumors 
exhibited an increased abundance of transcripts associated with innate immune responses; in particular, mRNA 
expression of pro-inflammatory mediators linked to intestinal tumorigenesis such as Il1b13,30,31, Il69,10, Il1732–35, 
Il2211,12, Ccl236 and Cxcl237–39 was augmented compared to Trem1−/− tumors (Fig. 2a,b). Pathway analysis further 
identified neutrophil chemotaxis, TNF signaling and cellular extravasation as major differentially regulated path-
ways (Supplementary Table 2). In contrast, Trem1−/− tumors exhibited increased mRNA expression of molecules 
associated with immune regulation or adaptive immune stimulation (Fig. 2a and Supplementary Table 1). Since 
the anti-tumoral immune activity to AOM/DSS-induced CRC tumors is mainly mediated by cytotoxic CD8+ 
T cells, whose function is controlled by regulatory FOXP3+ T cells (Tregs)40, we examined whether TREM-1 
signaling negatively regulates the generation of Tregs in CRC lesions of Trem1+/+ mice. However, absence of 
TREM-1 did not affect the expression of Foxp3 transcripts in AOM/DSS CRC tumors (Supplementary Figure 2) 
thus, suggesting that Tregs did not contribute to the observed differences between these tumors (Supplementary 
Figure 2b). When comparing additional genes that were included in the NanoString mouse immunology 
panel, the expression of markers associated with neutrophils but not monocytes/macrophages was increased 
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in Trem1+/+ tumors whereas Trem1−/− tumors displayed augmented expression of markers associated with B 
cells or follicular helper T cells (Supplementary Figure 2). Importantly, the above-described differences in gene 
expression were only observed for bona fide intestinal tumors but not for adjacent tumor-free colonic mucosa 
(Fig. 2b). As seen for inflammatory genes such as Il1b and Il6, also the expression of Trem1 was highly increased 
in Trem1+/+ tumors as opposed to matched tumor-free colonic mucosa (Fig. 2b).
In summary, presence or absence of TREM-1 had a distinct impact on the intratumoral immune transcrip-
tome. While Trem1+/+ tumors exhibited a transcriptional pattern typically associated with the inflammatory 
microenvironment of colorectal tumors, the immune signature of Trem1−/− mice was reminiscent of the Tfh/B 
cell axis that has previously been associated with a favorable prognosis in human CRC6.
Flow cytometry analysis indicates increased abundance of neutrophils in Trem1+/+ tumors. 
We next aimed to assess the cellular infiltrates in Trem1+/+ versus Trem1−/− tumors. In situ analysis of MPO (neu-
trophils), F4/80 (macrophages) and B220 (B cells) expression on immunostained tumor sections did not indicate 
apparent differences between the two groups of mice (data not shown). Therefore, we decided to use flow cytom-
etry for a detailed characterization of the cellular infiltrates in Trem1+/+ versus Trem1−/− tumors. We additionally 
included analysis of non-inflamed colons from untreated control mice, inflamed colons that were taken after 
the 3rd DSS cycle, as well as tumor-free colonic mucosa at the final time-point. As anticipated, for non-inflamed 
colons no substantial differences between the two groups were observed; neutrophils and inflammatory Ly6C+ 
monocytes were hardly detectable and myeloid cells mostly consisted of resident Ly6C- MHCII+ macrophages 
(Fig. 3a). After the 3rd DSS cycle, colons from Trem1+/+ and Trem1−/− mice showed a prominent increase in infil-
trating neutrophils, Ly6C+ MHCII− monocytes and also a subset of Ly6C+ MHCII+ cell representing monocyte/
macrophage intermediates (Fig. 3a,b and see Supplementary Figure 3a for full gating strategy). At the end of the 
observation period, myeloid cell populations in the tumor-free colon were comparable to those seen in untreated 
non-inflamed controls; however, neutrophils were still present at elevated frequencies, particularly in Trem1+/+ 
mice (Fig. 3a,b). Strikingly, in Trem1+/+ tumors the relative abundance of neutrophils was even further increased, 
with Ly6G+ neutrophils representing up to 40% of tumor-infiltrating CD45+ leukocytes (Fig. 3a,b). While analy-
sis of Trem1−/− tumors had to be restricted to a single sample of pooled tumors from several mice, the frequency 
of Ly6G+ neutrophils was clearly much lower (Fig. 3a,b). In contrast, Trem1−/− tumors exhibited a drastically 
higher proportion of CD19+ B cells (Fig. 3b). The differences in cellular infiltration were not related to tumor size, 
as the size distribution of tumors selected for flow cytometry was comparable between the two groups of mice 
(Supplementary Figure 4a,b). Moreover, there was no significant correlation between tumor size and abundance 
of neutrophil-associated transcripts (Cxcr1, Cxcr2) (Supplementary Figure 4c,d). Taken together, the flow cytom-
etry analysis corroborated the notion that tumors of Trem1+/+ and Trem1−/− mice mostly differed in the extent of 
tumor-infiltrating neutrophils versus B cells.
Figure 1. Deficiency in TREM-1 attenuates colitis-associated tumorigenesis. Mice were subjected to AOM/
DSS and analyzed 80 days post initial AOM injection (a) Scheme of treatment protocol. (b) Macroscopic 
pictures of representative colons of Trem1+/+ and Trem1−/− mice. Arrow heads indicate macroscopically visible 
tumors. (c,d) Number of tumors and total tumor load per colon. (e) Tumor size distribution: Number of tumors 
within the indicated size category per colon. (c,d) Symbols represent data for individual Trem1+/+ (n = 18) and 
Trem1−/− (n = 17) mice, lines indicate mean values per group. Pooled data from two independent experiments 
are shown. Statistical testing was performed using the unpaired t-test (c), the Mann Whitney t test (d) and 2way 
ANOVA (e). ***p < 0.001; ****p < 0.0001.
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Figure 2. Distinct immune transcriptome in Trem1+/+ versus Trem1−/− tumors. (a) Heat-map of functionally 
defined subsets of mRNA transcripts that are differentially expressed in Trem1+/+ tumors (n = 10) compared 
to Trem1−/− (n = 11) tumors as determined by NanoString-based gene expression profiling. (b) qRT-PCR-
based analysis of functionally defined gene groups in tumors versus adjacent tumor-free colonic tissues from 
Trem1+/+ (n = 10) versus Trem1−/− mice (n = 11). Tumors were collected from individual mice at 80 days post 
initial AOM injection; from each mouse one tumor and one piece of tumor-free colonic mucosa were analyzed. 
Symbols show relative gene expression values (normalized to Gapdh) for individual mice, lines indicate mean 
values per group. (N.D.), not determined. Statistical testing was performed using 2way ANOVA. *p < 0.05; 
**p < 0.01; ***p < 0.001; ****p < 0.0001.
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Figure 3. Increased abundance of tumor-infiltrating neutrophils in Trem1+/+ mice. Colons from Trem1+/+ 
and Trem1−/− mice were analyzed by flow-cytometry either after the 3rd DSS cycle or at the final time-point. 
(a) Representative dot blots showing the relative frequency of live Ly6G+ neutrophils in CD11b+ cells and the 
“monocyte-waterfall”64 in live Ly6G− CD11b+ cells. (b) Relative frequencies of the indicated cell subsets among 
live CD45+ cells isolated from tumor-free colonic mucosa or tumors. (a,b) Analysis at the final time-point 
included n = 3 age-matched untreated control mice per group. For AOM/DSS treated mice at the final time 
point, tumor-free colonic mucosa and tumors were analyzed separately. In the Trem1+/+ group, tumors were 
pooled to yield one tumor sample per mouse; in the Trem1−/− group, tumors were pooled from n = 4 mice to 
yield a single tumor sample. Statistical testing was performed using 2way ANOVA.
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Tumor-infiltrating neutrophils represent the predominant TREM-1-expressing myeloid cell 
subset. Previous studies on the involvement of TREM-1 in hepatocellular carcinoma and lung cancer have 
suggested a role for TREM-1-expressing macrophages16,27,41. In the intestinal mucosa, TREM-1 is not detected 
on macrophages under homeostatic conditions42. While being highly expressed on infiltrating Ly6C+ monocytes 
and their Ly6C+ MHCII+ descendants in colitis, TREM-1 remains low on mature Ly6C- MHCII+ macrophages 
even during inflammation (Supplementary Figure 3a,b)43,44. Since expression of TREM-1 can be induced by 
tumor-derived factors41,45, we nonetheless considered the possibility that macrophages in colorectal tumors 
expressed TREM-1. However, Ly6C− MHCII+ macrophages in Trem1+/+ tumors did not exhibit appreciable 
expression of TREM-1 (Fig. 4a,b). Whereas TREM-1 was present on Ly6C+ MHCII+ intermediate monocyte/
macrophages, the relative abundance of these cells among CD45+ cells was very low (Fig. 4a,c). In contrast, 
TREM-1 was highly expressed on tumor-infiltrating Ly6G+ neutrophils which also represented the predominant 
myeloid cell subset in Trem1+/+ tumors (Fig. 4a–c).
TREM1 is expressed in human colorectal cancer. We next sought to determine whether TREM-1 is 
expressed in human colorectal tumors and whether TREM-1 expression in human CRC would also associate 
with neutrophils. To this end, we performed qRT-PCR on RNA isolated from formalin-fixed paraffin-embedded 
(FFPE) human CRC tissue specimens and the corresponding non-tumor tissue. In 6/8 cases analyzed, increased 
mRNA for TREM-1 was indeed detected in the tumor as opposed to the non-tumor tissue (Fig. 5a). The expres-
sion pattern of TREM1 was closely paralleled by the expression of IL1B and S100A9 which were also increased 
in the tumor tissue (Fig. 5a). In contrast, no differences in mRNA expression levels of CD14 and CD68 could be 
detected between tumor and non-tumor tissues (Fig. 5a). Immunohistochemistry staining for the granulocyte 
marker CD15 on sections from TREM1 low- versus TREM1 high-expressing tumors indicated that augmented 
expression of TREM1 in human CRC also appeared to associate with increased neutrophil infiltration (Fig. 5b).
Discussion
TREM-1 is now emerging as a central player not only during acute pathogen-induced reactions but also in 
chronic and non-infectious inflammatory disorders20–23. Pioneering studies have further indicated an involve-
ment of TREM-1 in various types of malignancies, including leukemia46,47, NSCLC27,28,41, HCC16,48 and CRC29. 
Here, using an inflammation-driven model of CRC and mice genetically deficient in Trem1, we have established a 
clear role for TREM-1 in intestinal tumorigenesis, demonstrating that Trem1−/− mice show significantly reduced 
tumor development.
Figure 4. Tumor-infiltrating neutrophils but not tumor-associated macrophages express TREM-1. (a) 
Representative staining panels of a Trem1+/+ tumor sample showing the relative frequency of live Ly6G+ 
neutrophils among tumor-infiltrating CD11b+ cells and the “monocyte-waterfall”64 in live Ly6G− CD11b+ cells. 
Histograms show TREM-1 surface expression (lines; filled histograms represent isotype control-stained cells) 
in the indicated cell subsets. (b) Mean fluorescence intensity (MFI) of TREM-1 expression in the indicated cell 
subsets. (c) Relative frequency of the indicated cell subsets among live CD45+ tumor-infiltrating cells. Symbols 
represent data for individual mice (n = 7); lines show mean values per group. N.D., not detected.
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The attenuated tumor development in Trem1−/− mice may be considered a consequence of their diminished 
inflammatory response reported in distinct models of experimental colitis24,25. However, besides providing direct 
evidence for a tumor-promoting role of TREM-1 in vivo, our study reveals two novel findings: First, in the AOM/
DSS model of CRC, tumor-infiltrating neutrophils, but not TAMs, represent the major TREM-1-expressing cell 
subset. Other reports from distinct tumor models previously described a major role for TREM-1 on TAMs for 
tumorigenesis16,27,41. Second, the absence of TREM-1 affects the intratumoral immune signature with a shift 
towards an overrepresentation of transcripts related to B cells and Tfh cells in Trem1−/− tumors. In contrast, 
Trem1+/+ tumors exhibited an innate immune signature typically linked to intestinal tumorigenesis, including 
enhanced expression of pro-inflammatory cytokines and neutrophil-associated markers.
Former studies investigating the potential role of TREM-1 in cancer have either correlated the in situ 
expression of TREM-1 with clinicopathological data27,48–50, employed in vitro co-cultures of cancer cells with 
macrophages27,41, or have interfered with TREM-1-mediated signaling using in vivo tumor models16,28,29. 
Figure 5. TREM1 is expressed in human colorectal tumors. (a) Expression of TREM1 and IL1B as well as 
S100A9, CD14 and CD68 was determined in human colorectal cancer tissue and matched tumor-free mucosa 
by qRT-PCR. Expression of genes of interest was normalized to the expression of GAPDH. (b) Representative 
images of tumor sections stained for the granulocyte marker CD15. One image is from a tumor with low 
TREM1 expression, the other image illustrates CD15 expression on a tumor with high TREM1 expression. Scale 
bars represent 100 μM. (a) Symbols show data for n = 8 colorectal cancer patients; lines indicate mean values. 
Statistical testing was performed with the Wilcoxon matched-pairs signed rank test. *p < 0.05.
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Collectively, these findings suggest that distinct tumors can induce the expression of TREM-1 on monocytes/
macrophages27,41,45 and that expression of TREM-1 in human cancer tissue can serve as a powerful prognostic 
indicator27,48–50. In murine models, the tumor-promoting function of TREM-1 was associated with augmented 
expression of several pro-inflammatory mediators and increased compensatory proliferation of parenchymal 
cells16,29. In their seminal paper, Wu et al. were further able to directly demonstrate that TREM-1-activated 
Kupffer cells were required and sufficient to promote hepatocellular carcinoma development in response to liver 
injury16.
In view of the proposed significance of TREM-1 expression by macrophages in distinct types of cancer16,27,41, 
it is intriguing that in murine colorectal tumors Ly6C− MHCII+ TAMs were evidently TREM-1 negative. This 
appeared to be a consistent trait and did not reflect a premature time-point of analysis since in more advanced 
and larger colorectal tumors TAMs equally lacked TREM-1 expression (data not shown). Although cleavage of 
TREM-1 from activated cells could account for reduced cell surface expression, we did not consider such a sce-
nario a likely explanation for the complete absence of surface TREM-1 on colorectal TAMs, in particular, since 
TREM-1 was still highly expressed by infiltrating neutrophils and a small subset of Ly6C+ MHCII+ intermediate 
monocytes/macrophages. Rather we believe that analogous to the situation in the inflamed colonic mucosa where 
resident Ly6C− MHCII+ macrophages largely retain their hyporesponsive signature and remain TREM-1low/− 43,44, 
macrophages in colorectal tumors are also relatively inert to pro-inflammatory stimuli in their local environment, 
at least with respect to an upregulation of TREM-1. Alternatively, newly recruited monocytes may downregulate 
TREM-1 expression because of the TGFβ and IL-10-rich environment of the colonic mucosa or as part of a 
default tissue-specific differentiation program42,51. Unlike the previously described upregulation of TREM-1 on 
peripheral blood Gr1+ monocytes in RMA-S tumor-bearing mice45, we did not detect substantial changes in sur-
face TREM-1 expression on any peripheral blood myeloid cell subset isolated from mice with colorectal tumors 
as opposed to age-matched untreated controls. Similarly, TREM-1 expression on neutrophils was comparable in 
neutrophils isolated from healthy colonic tissue of untreated control mice, AOM/DSS-induced tumors, as well 
as adjacent tumor-free, colonic tissues of treated mice (data not shown). Interestingly, a recent study has even 
reported progressive loss of TREM-1 on tumor-infiltrating monocytes/macrophages in a mouse lung carcinoma 
model and proposed TREM-1low expression as a novel characteristic for TAMs in human NSCLC tissue52. Thus, 
the expression and functional significance of TREM-1 on cells of the monocyte/macrophage lineage seems to 
depend on the tissue-dependent context or the nature of tumor-associated inflammation and calls for further 
investigation across distinct types of cancer.
Although TREM-1 is constitutively expressed by neutrophils and neutrophil-lymphocyte ratios are increas-
ingly incorporated in prognostic scores53, to the best of our knowledge a function for TREM-1-expressing neu-
trophils has so far not been considered in any of the studies addressing the role of TREM-1 in cancer. This may 
relate to the distinct nature of tumor-eliciting or tumor-associated inflammation in the other types of cancer 
analyzed so far. In line with the microbial-driven neutrophilic inflammation that is induced by DSS treatment, 
we demonstrate here that in murine colorectal tumors TREM-1 is mainly expressed by neutrophils, which also 
represent the predominant myeloid cell population in Trem1+/+ tumors. While we could not absolutely quantitate 
differences in tumor infiltrates between the Trem1+/+ or Trem1−/− group (in Trem1+/+ mice, tumors had to be 
pooled as they were too numerous for separate analyses, in Trem1−/− mice, tumors were so small and scarce that 
they were pooled into a single sample in order to acquire sufficient cells), an increased abundance of neutrophils 
in Trem1+/+ as opposed to Trem1−/− tumors was also strongly suggested by NanoString- and qRT-PCR-based 
gene expression profiling of individual tumors. Accordingly, irrespective of their size, Trem1+/+ tumors exhibited 
an increased abundance of neutrophil-associated transcripts such as Itgam, Cxcr1, Cxcr2 and S100a8/S100a9. 
Neutrophil chemotaxis was also identified as a major differentially regulated pathway, since increased levels 
of Cxcl1 and Cxcl2 transcripts were detected in the Trem1+/+ tumors. Although the upregulated expression of 
neutrophil-specific chemokines may only be an indirect consequence of TREM-1 signaling, these data thus 
provide circumstantial evidence for a TREM-1-dependent recruitment of neutrophils into colorectal tumors in 
the AOM/DSS model. Indeed, numerous studies involving both spontaneous and inflammation-driven models 
of CRC have documented the prominent infiltration of murine colorectal tumors with neutrophils and have 
directly demonstrated beneficial effects of genetic deficiency in Cxcr2 or targeted neutrophil depletion on tumor 
development and progression13,37–39. The tumor-promoting effects of neutrophils were ascribed to production of 
nitric oxide radicals contributing to DNA damage54, to expression of metalloproteinase (MMP)-9 and neutrophil 
elastase (NE) driving angiogenesis and enhanced tumor cell proliferation38, to myeloid-derived suppressor cell 
(MDSC) activity and inhibition of CD8+ T cell functions36, and also to increased pro-inflammatory chemokine 
and cytokine secretion. Along with augmented expression of neutrophil-associated chemokines and markers, 
we observed significantly higher levels of transcripts for pro-tumorigenic Il1b and Il655 and potential down-
stream molecules such as Il17a, Il22, Jak3 and Stat3 in Trem1+/+ as opposed to Trem1−/− tumors. In addition, 
in human CRC samples upregulated expression of TREM1 was associated with increased IL1B expression. The 
pro-tumorigenic effects of IL-1β were previously ascribed to induction of IL-6 secretion by mononuclear phago-
cytes13,55 which was also expressed at higher levels in Trem1+/+ tumors (Fig. 2). While we could not directly deter-
mine the cellular sources of these cytokines in our model, it is likely that TREM-1-activated neutrophils at least 
partly contribute to CRC development via their augmented secretion of pro-inflammatory factors. The increased 
induction of chemotactic mediators along with the reported improved survival of neutrophils upon TREM-1 
stimulation25 likely account for the accumulation of neutrophils in the colons of AOM/DSS-treated Trem1+/+ 
mice. Since presence of TREM-1 mostly seems to impact on the incidence of small tumors rather than the growth 
of large tumors, this implies that TREM-1-expressing neutrophils may primarily contribute to early tumorigene-
sis, particularly, as TREM-1 signaling strongly induces iNOS and ROS production25,56. However, we believe that 
the effects of TREM-1-activated neutrophils on tumor development are likely multilayered and operative also in 
established tumors.
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One limitation of the AOM/DSS model of CRC is that tumors do not generally metastasize in C57BL/6 mice3. 
Therefore, we were not able to address the previously postulated association between TREM-1 and cancer pro-
gression27,49,50 with our in vivo model. However, we found that the immune signature of Trem1+/+ and Trem1−/− 
tumors not only differed with respect to the increased expression of pro-inflammatory genes in Trem1+/+ tumors, 
but that Trem1−/− tumors were characterized by an increased abundance of transcripts related to adaptive 
immune stimulation, B cells and Tfh cells. The expression of these markers and transcription factors such as Ikzf1, 
Pax5 and Rorc is reminiscent of tertiary lymphoid tissue (TLT) formation which has been associated with a better 
prognosis in early-stage CRC57. Indeed, in their comprehensive study on the human intratumoral immune land-
scape, Bindea et al., established CXCR5/CXCL13 and the Tfh/B cell axis as major antitumor players and powerful 
markers for predicting prolonged patient survival6. It is currently unclear why the Trem1−/− tumor environment 
favors an accumulation of B cells. This phenomenon may relate to the decreased genomic stability of Cxcl136 or 
to a retinoic acid deficit58 in the context of the increased intestinal inflammation in Trem1+/+ tumors as both 
factors have been implicated in lymphoid tissue formation59. However, further investigation will be necessary to 
conclusively address this aspect.
Notably, RNA-sequencing analysis of human CRC specimens at various stages has identified TREM1 as one 
of two predominant regulators activated during CRC tumorigenesis and a risk score based on nineteen genes 
regulated by TREM1 and CTGF represented a significant prognostic indicator for CRC aggressiveness50. Hence, 
the expression and prognostic significance of TREM-1 in human CRC clearly warrants further investigation.
In summary, our study demonstrates that TREM-1 critically contributes to inflammation-driven intestinal 
tumorigenesis. Our data may further challenge the current notion that TREM-1+ macrophages may be the crit-
ical players across all types of cancer by identifying neutrophils as the major TREM-1-expressing cell subset in 
the AOM/DSS model of inflammation-induced CRC. While the precise mechanisms behind TREM-1-mediated 
tumor development still need to be deciphered, our findings show that intratumoral expression of Trem1 asso-
ciates with increased expression of pro-inflammatory genes implicated in intestinal tumorigenesis. Considering 
the well-established link between innate inflammation and cancer, TREM-1 may emerge as a powerful prognostic 
indicator not only in CRC but across several types of cancer. Finally, our results suggest that therapeutic inhibi-
tion of TREM-1 may not only prevent onset of cancer in patients with IBD, but that TREM-1 could represent a 
novel immunotherapeutic target to restrain cancer-promoting inflammation without jeopardizing anti-microbial 
and anti-tumor immunity.
Materials and Methods
Mice. Trem1−/− mice (on the C57BL/6 background) were generated in our laboratory as described previ-
ously25. Trem1+/+ wildtype mice represented former littermates of Trem1−/− mice. Trem1+/+ and Trem1−/− mice 
were bred and maintained in isolated ventilated cages at the central animal facility of the University of Bern. 
Experiments were initiated with 10 weeks old sex-matched Trem1+/+ and Trem1−/− mice. Prior to and during the 
experiments, soiled bedding was exchanged to match commensal communities between experimental groups. 
Experiments were performed in accordance with Swiss Federal regulations and were approved by the Cantonal 
Veterinary Office.
Induction and assessment of AOM/DSS-induced colorectal cancer. As a model for murine CRC, 
we used the AOM/DSS model which included in our protocol two i.p. injections of AOM (Sigma, Switzerland, 
Cat. No. A5486) and three cycles of 1% DSS (MP Biomedicals, Cat. No. 160110) administered in the drinking 
water60. Briefly, mice were injected with 10 mg/kg AOM and rested for 6–7 days prior to the 1st DSS cycle (5 days). 
After 6–7 days on regular water, mice received a 2nd injection of AOM and an additional 3-day rest on water 
before the 2nd DSS cycle (4 days). Thereafter, mice were rested for up to 13 days before the 3rd DSS cycle (3 days). 
From this, mice were placed on water until approximately 80 days post the initial AOM injection. Throughout 
the entire course of the experiment, mice were monitored regularly for their overall well-being and changes in 
their body weight. Macroscopic tumors were counted independently by two observers. Tumor load was meas-
ured with a pair of sliding calipers and calculated as (W × L × H) × π/6 as previously described60. Formalin-fixed 
paraffin-embedded and H&E stained tumors sections were graded by a board-certified pathologist in a blinded 
manner according to criteria defined in the legend to Supplementary Figure 1.
RNA isolation and gene expression analysis. From each mouse, one randomly selected tumor was 
placed in RNAlater (Life Technologies, USA). For RNA isolation, tumors were transferred into TRI Reagent 
(Sigma) and tissues were homogenized with a TissueLyser (Qiagen). RNA was isolated according to the man-
ufacturer’s instructions. For NanoString-based gene expression profiling, the nCounter Mouse Immunology 
panel was used (NanoString technologies, Seattle, USA). Samples were analyzed at the Genomics Platform of the 
University of Geneva (GE3, University of Geneva, Switzerland). mRNA expression of particular genes of interest 
was confirmed by qRT-PCR. Briefly, contaminating genomic DNA was digested with DNase I (Ambion) and 
cDNA was generated with the High Capacity Reverse Transcription Kit (Applied Biosystems). qRT-PCR reactions 
were set up with a SYBR-green based reaction mix (Roche, Switzerland) and Quantitect primers (Qiagen) and 
analyzed on a 7500 Real-time PCR System (Applied Biosystems). Expression of candidate genes was normalized 
to the house-keeping gene Gapdh, multiplied by a factor of 1000 and depicted as relative amount of mRNA (to 
Gapdh).
Cell isolation from murine colons and tumors. Tumor-free colons and colon sections were opened lon-
gitudinally and cut into small pieces. Epithelial cells were removed by incubation of tissue pieces in HBSS/HEPES 
containing 5% FCS, 2 mM EDTA for 2 × 15 min at 37 °C under magnetic stirring. After washing of tissue pieces 
with EDTA-free buffer, lamina propria (LP) cells were obtained by digestion with 100 U/ml Collagenase (Type IV, 
www.nature.com/scientificreports/
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Sigma) and 50 U/ml DNase (Type I, grade II, Roche) in Ca2+ and Mg2+-supplemented HBSS/HEPES 5% FCS for 
20–30 min at 37 °C. For isolation of cells from tumors, tumors were carefully excised from the tumor-free mucosa 
and transferred into 15 ml U-bottom tubes with small magnetic stirrers (larger tumors were additionally minced 
with a scalpel). Pooled tumors were subsequently digested in Ca2+ and Mg2+-supplemented HBSS/HEPES 5% 
FCS with 100 U/ml collagenase (Type IV), 50 U/ml DNase (Type I) and 150 U/ml hyaluronidase (Type V, Sigma) 
for 45′ at 37 °C. Cell suspensions from tumors and tumor-free colons were passed through a 70 μM cell strainer 
and further characterized by flow cytometry.
Antibodies and flow cytometry. Cell suspensions were Fc-Receptor blocked and stained with the fol-
lowing antibodies (all from Biolegend unless indicated otherwise): (Myeloid panel) anti-Ly6G-FITC (1A8; 1.25 
μg/ml), anti-CD64-PE (X54-5/7.1; 2 μg/ml), anti-CD11c-PerCP-Cy5.5 (N418; 1 μg/ml), anti-CD11b-PE-Cy7 
(M1/70; 0.2 μg/ml), anti-Ly6C-AlexaFluor700 (HK1.4; 2 μg/ml), anti-MHCII-APC-Cy7 (M5/114.15.2; 
0.067 μg/ml), anti-TREM-1-eFluor660 (TR3MBL1 from eBioscience; 0.2 μg/ml), anti-CD45-BrilliantViolett 
(30-F11; 1 μg/ml). (Lymphocyte panel) anti-CD8b-FITC (53-5.8; 0.8 μg/ml), anti-TCRab-PE, 
anti-GL7-PerCP-Cy5.5 (GL7; 1 μg/ml), anti-CD19-PE-Cy7 (6D5; 0.5 μg/ml), anti-CD11b-PacificBlue (M1/70; 
0.25 μg/ml), anti-NK1.1-AlexaFluor700 (PK136; 2.5 μg/ml), anti-CD4-APC-Cy7 (RM4-5; 0.25 μg/ml), 
anti-BTLA-AlexaFluor647 (6A6; 2.5 μg/ml), anti-CD45-BrilliantViolett (30-F11; 1 μg/ml). As an isotype control 
for the anti-TREM-1-e-Fluor660 a mouse anti rat IgG2a-eFluor660 antibody (eBR2a; 0.2 μg/ml) from eBiosci-
ence was used. Dead cells were excluded using DAPI (Invitrogen) at a final concentration of 0.5 μg/ml. All sam-
ples were acquired on a LSRII SORP (BD Biosciences, San Diego, CA) and analyzed using the FlowJo Software 
(Tree Star, Ashland, OR).
Human CRC tissue specimens. Human FFPE CRC tissue specimens were collected at the Institute of 
Pathology, University of Bern and analyzed in concordance with Swiss regulations for retrospective research 
on human tissue specimens collected for diagnostic purposes before 06/2014 and following the approval by the 
Ethics Committee Bern for which written consent was not required prior to the implementation of the Swiss law 
on human research (“Humanforschungsgesetz”) in 2014.
Suitable CRC specimens and corresponding tumor-free normal mucosa were selected from a total of eight 
patients based on the prior analysis of the case history and H&E-stained sections. RNA from five 10 μM thick 
FFPE tissue sections was purified using a column-based approach described by Oberli et al.61. SYBR-green based 
qRT-PCR was performed with QuantiTect (Qiagen) primers as described above. Immunostainings for CD15 
were performed on an automated platform (Leica Bond RX, Leica Biosystems, Switzerland) using the anti-CD15 
monoclonal antibody clone MMA (BD Biosciences).
Statistical analysis. All data except for NanoString data were analyzed using Prism software version 6.0c. 
Statistical tests were performed as described in the figure legends. In general, the D’Agostino & Pearson omnibus 
K2 normality test was performed to determine whether the samples were distributed according the Gaussian dis-
tribution. For normally-distributed samples the unpaired t test was performed; for samples without Gaussian dis-
tribution, the Mann Whitney t test was used. Only statistically significant differences are indicated in the figures. 
For analysis of the NanoString data, significant differences in gene expression were calculated between Trem1+/+ 
and Trem1−/− tumors. Gene expression values were first log-transformed. The Bioconductor limma package was 
used to perform a moderate t-test on all genes62. Pathway analysis was performed using the SetRank tool63. The 
heat-map was constructed in R.
Availability of data. All relevant data that support the findings of this study, including the full NanoString 
gene expression profiling data, are available from the corresponding authors upon request.
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